Pharmacotherapy of pediatric and adolescent HIV infection by Schuval, Susan J
© 2009 Schuval, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Therapeutics and Clinical Risk Management 2009:5 469–484
Therapeutics and Clinical Risk Management
469
R e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Pharmacotherapy of pediatric and adolescent 
Hiv infection
Susan J Schuval1,2
1Division of Allergy/immunology, 
Department of Pediatrics, North 
Shore – Long island Jewish Health 
System, Great Neck, NY, USA; 
2Associate Professor of Clinical 
Pediatrics, Albert einstein College 
of Medicine, Bronx, NY, USA
Correspondence: Susan J Schuval 
Division of Allergy/immunology, 865 
Northern Boulevard, Suite 101, Schneider 
Children’s Hospital, Great Neck, NY 
11021, USA 
Tel +1 516 622 5070 
Fax +1 516 622 5060 
email schuval@lij.edu
Abstract: Significant advances have been made in the treatment of human immunodeficiency 
virus (HIV) infection over the past two decades. Improved therapy has prolonged survival and 
improved clinical outcome for HIV-infected children and adults. Sixteen antiretroviral (ART) 
medications have been approved for use in pediatric HIV infection. The Department of Health 
and Human Services (DHHS) has issued “Guidelines for the Use of Antiretroviral Agents in 
Pediatric HIV Infection”, which provide detailed information on currently recommended anti-
retroviral therapies (ART). However, consultation with an HIV specialist is recommended as 
the current therapy of pediatric HIV therapy is complex and rapidly evolving.
Keywords: antiretroviral, HAART, Pediatric Guidelines, HIV, AIDS
Introduction
The first cases of pediatric Acquired Immunodeficiency Syndrome (AIDS) were 
described in the United States (US) in 1983.1 At that time, no specific antiretroviral 
(ARV) medications were available to children infected with HIV, most of whom suc-
cumbed to their infection. In 1990, zidovudine became the first approved pediatric ARV 
medication. HIV-infected children received zidovudine monotherapy with some clinical 
improvement but HIV infection remained a fatal disease. However, with the evolution 
of highly active antiretroviral therapy (HAART) during the 1990’s, HIV-associated 
morbidity and mortality declined greatly, and HIV infection became a treatable and 
chronic disease for both adults and children. At the present time, most HIV-infected 
children in the US are surviving through adolescence to adulthood. In the US, most 
children acquire HIV via perinatal transmission, although infection may be acquired 
behaviorally (sexually or via injection drug use) in adolescents.
Currently, there is no cure for HIV infection and viral eradication is not possible 
at this time. However, viral suppression to undetectable levels can be achieved 
by individualization of therapy, with careful selection of initial and subsequent 
treatment regimens. Maximal viral suppression is associated with delayed HIV 
disease progression and improved survival.2 Maintaining adherence to prescribed 
regimens, preventing short-term and long-term drug toxicities, and managing drug-
resistance in HIV-infected children and adolescents receiving ART are the main 
challenges faced today in the treatment of pediatric HIV infection. Although many 
of the medications used for treatment are the same as those used in adults, issues 
unique to pediatric HIV infection include differences in mode of viral acquisition, 
immaturity of the immune system, and considerations of growth and development, Therapeutics and Clinical Risk Management 2009:5 470
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especially during puberty. Treatment decisions must 
include consideration of the child’s age, treatment readi-
ness, psychosocial milieu, past treatment history, as well 
as available drug formulations and treatment schedule. 
Possible drug teratogenicity must be considered in the 
treatment of adolescents who may be sexually active. 
Goals of ART include reduction of HIV-associated morbid-
ity and mortality, preservation or restoration of immune 
function, and reduction of HIV viral replication. Whenever 
possible, consultation with a specialist in the treatment of 
pediatric or adolescent HIV infection is recommended as 
the current therapy of pediatric HIV infection is complex 
and rapidly evolving.
This review summarizes the current “Guidelines for the 
Use of Antiretroviral Agents in Pediatric HIV Infection.”3 
The ARV medications discussed below apply primarily to 
highly resourced settings such as the US. Although zidovu-
dine given perinatally to mother and child has been proven 
to successfully interrupt perinatal HIV transmission, use of 
post-exposure prophylaxis will not be discussed here nor 
will prophylaxis and treatment of opportunistic infections 
in HIV-infected children.4,5
HIV virology/Life cycle
HIV-1 is a human retrovirus which contains the enzyme 
reverse transcriptase. During acute HIV infection, the viral 
envelope glycoprotein gp 120 binds to the CD4 receptor 
on the mature human helper T lymphocyte (CD4 cell). 
Subsequently, the viral envelope binds to 1 of 2 chemo-
kine coreceptors, either CXCR4 (X4) or CCR5 (R5). Most 
viral isolates acquired via sexual transmission utilize the 
R5 chemokine receptor (R5-tropic) while X4 viral strains 
tend to predominate in more advanced HIV infection 
(X4-tropic). A conformational change then ensues, resulting 
in fusion of the viral envelope with the CD4 cell membrane, 
after which the HIV viral RNA enters the cell cytoplasm.6 
The viral reverse transcriptase then transcribes the single-
stranded viral RNA into host double stranded DNA. The 
viral enzyme integrase inserts the proviral DNA into the 
host genome via a strand transfer reaction. During subse-
quent activation of this infected CD4 T cell, the integrated 
proviral DNA is translated into new viral proteins. Assem-
bly of these viral products then occurs on the cell surface, 
followed by budding of immature viral particles. The viral 
enzyme protease aids in the production of final infectious 
virions by cleaving viral polyprotein precursors, and gen-
erating new viral proteins. Active viral replication then 
occurs, eventually decreasing over time to a steady state 
level. A progressive immunodeficiency is seen over time, 
which may culminate in the occurrence of opportunistic 
infections, malignancy, and death.
Overview of antiretroviral 
medications
Since 1996, 31 ARVs have been approved for use, with 16 of 
these approved for use in children (Table 1). Three of these 
medications (zalcitabine, amprenavir, and delavirdine) are 
no longer manufactured. There are currently six classes of 
medications for treatment of HIV infection that block vari-
ous stages of the HIV life cycle by targeting key enzymes. 
ARVs such as reverse transcriptase inhibitors (both nucleoside 
reverse transcriptase inhibitors and non-nucleoside reverse 
transcriptase inhibitors), integrase inhibitors, and protease 
inhibitors prevent replication of the viral genome and intracel-
lular viral maturation. Fusion inhibitors and CCR5 antagonists 
block the entry of virus into the CD4 cell either by interfering 
with viral fusion or co-receptor binding. Nucleoside reverse 
transcriptase inhibitors, non-nucleoside reverse transcriptase 
inhibitors, and protease inhibitors all have pediatric indica-
tions, while entry inhibitors, CCR5 antagonist, and integrase 
inhibitors are newer agents used primarily for the treatment of 
multidrug-resistant HIV infection in adults. Pediatric experi-
ence with these newer medications is limited and their use 
is only currently recommended in cases of treatment failure. 
Most of the data regarding pediatric HIV treatment are derived 
from adult data or Phase I/II clinical trials as few phase III 
ART clinical trials have been performed in HIV-infected 
children. However, HAART regimens have been shown to be 
safe efficacious, and durable in HIV-infected children, even 
with longterm use.7–9
The following will serve as an overview of the medica-
tions currently used in the treatment of HIV-infected children 
and adolescents. More detailed information on each medica-
tion can be found elsewhere.3
Classes of antiretroviral 
medications
Nucleoside reverse transcriptase 
inhibitors (NRTis)
NRTIs were the first class of ARV medications approved for 
the treatment of HIV infection. NRTIs inhibit the viral enzyme 
reverse transcriptase, preventing transcription of viral RNA 
into host DNA. These nucleoside analogues are prodrugs 
that require intracellular phosphorylation for activation. The 
6 NRTIs currently approved for use in HIV-infected children Therapeutics and Clinical Risk Management 2009:5 471
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include zidovudine, stavudine, lamivudine, emtricitabine, 
didanosine, and abacavir (Table 1). NRTIs are currently 
recommended for use in all pediatric ART regimens as part 
of a dual NRTI backbone.3 NRTIs have few side effects and 
are mostly well-tolerated with good bioavailability. NRTIs 
such as zidovudine penetrate into cerebrospinal fluid and may 
be useful in the treatment of HIV-associated neurocognitive 
disorders. NRTIs have few drug interactions and are mostly 
eliminated via the kidneys, necessitating possible dose adjust-
ment in renal failure. Use of NRTIs has been linked with mito-
chondrial toxicity, which may present as cardiomyopathy, 
myopathy, peripheral neuropathy, pancreatitis, renal tubular 
dysfunction, hepatic steatosis, and lactic acidosis, all of which 
occur more often in adults than children.
Thymidine analogues
Zidovudine (Retrovir®)
Zidovudine was the first ARV medication ever approved. It 
is available in liquid, capsule, tablet, and a concentrate form 
for injection or intravenous infusion. The oral form is usually 
administered twice daily (thrice daily in younger children), 
with the dose determined by weight or body surface area. 
Although it is generally well-tolerated by children, bone 
marrow suppression may occur, resulting in anemia and 
leukopenia. Other common side effects include headache, 
malaise, and gastrointestinal symptoms such as nausea, 
vomiting, and anorexia. Myopathy, myositis, liver toxicity, 
and fat redistribution are less common side effects.10,11
Stavudine (Zerit®)
Stavudine is available as a capsule or solution for twice daily 
administration. Common toxicities include headache, rash, 
and gastrointestinal symptoms. Less common side effects 
include peripheral neuropathy, lipodystrophy, serum trans-
aminase elevation, and neuromuscular weakness. Although 
use of all NRTIs has been linked to lipoatrophy and hyper-
lactatemia, this effect is seen more often with stavudine.12 
Thus, at the present time, use of stavudine is limited to special 
circumstances (such as a young child with human leukocyte 
antigen [HLA] B*5701 who cannot be given abacavir, or a 
child with anemia who may experience additional hemato-
logic suppression from zidovudine).3
Nonthymidine analogues
Lamivudine (epivir®)
Lamivudine is a cytosine analogue that has been extensively 
studied in HIV-infected children.11,13 It is available both as 
an oral solution and a tablet, that are well-tolerated with few 
side effects (headache, fatigue, anorexia, rash, abdominal 
pain, and insomnia). Less common side effects include pan-
creatitis, peripheral neuropathy, anemia, neutropenia, serum 
transaminase elevation, and fat redistribution.
emtricitabine (emtriva®)
Emtricitabine is a pyrimidine nucleoside analogue that is a 
fluorinated derivative of lamivudine. It was approved in 2003 
for once daily dosing and is available in a palatable liquid 
formulation. Emtricitabine was shown to be safe, well toler-
ated, and durable in the treatment of HIV-infected children 
as young as three months.14 Its longer half-life, higher oral 
bioavailability, and slightly greater potency in vitro led to its 
inclusion in combination with zidovudine over lamivudine as 
a preferred component of the dual NRTI backbone.3 It may 
be taken with or without food, and has few drug interactions. 
Side effects are generally mild and include rash, headache, 
insomnia, diarrhea, nausea, and vomiting. Less commonly 
seen adverse events include neutropenia and skin hyperpig-
mentation which has been reported in African-American 
patients receiving emtricitabine.
Didanosine (videx and videx eC®)
Didanosine is an adenosine analogue that is available as a 
delayed-release capsule for once daily administration or a 
pediatric powder for oral solution. Although didanosine is 
best absorbed on an empty stomach, pediatric pharmaco-
kinetic studies have shown that acceptable drug levels are 
achieved, although with delayed and slower absorption in 
children, when it is administered with food.15 The tablets 
and the oral solution contain antacids which may affect the 
absorption of other medications. Didanosine’s side effects 
are predominantly gastrointestinal, consisting of nausea, 
vomiting, diarrhea, and abdominal pain. Less commonly 
seen are peripheral neuropathy, electrolyte abnormalities 
and hyperuricemia. Pancreatitis, retinal changes, hepato-
toxicity, and optic neuritis have also been reported. The 
virologic efficacy of combined didanosine, emtricitabine, 
and efavirenz has been proven in pediatric trials, resulting in 
its selection as a preferred dual NRTI agent in combination 
with emtricitabine.3,16
Abacavir (Ziagen®)
Abacavir is a guanosine analogue that has been shown to 
be safe and efficacious for long-term use in HIV-infected 
children.13,17 The most common side effects associated 
with its use include nausea, vomiting, diarrhea, anorexia, 
fever, headache, and rash.18 Although abacavir is a potent Therapeutics and Clinical Risk Management 2009:5 473
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suppressor of viral replication, it has the potential to cause a 
life-threatening hypersensitivity reaction in genetically pre-
disposed individuals who possess the HLA allele B*5701. 
This hypersensitivity reaction occurs in 5%–8% of recipi-
ents, and consists of fever, rash, systemic, gastrointestinal 
and respiratory symptoms, usually during the first 6 weeks 
of therapy. Continuation of abacavir therapy has been asso-
ciated with increased severity of symptoms, and fatality. 
Rechallenge with abacavir is contraindicated in anyone 
reporting past hypersensitivity reaction. Pharmacogenetic 
testing for the HLA phenotype B*5701 is recommended 
prior to use in HIV-infected patients, and abacavir should 
be withheld from those who test positive for this allele. 
HIV-infected children and adults receiving abacavir should 
be informed of this risk of hypersensitivity reaction, and 
instructed to immediately contact their provider regarding 
abacavir discontinuation, if fever and rash occur.19 Other side 
effects of abacavir include nausea, diarrhea, abdominal pain, 
asthenia, headache, and elevation of serum transaminases 
or creatinine.
Nucleotide analogues
Tenofovir disoproxil fumarate (viread®)
Tenofovir disoproxil fumarate is a nucleotide analogue of 
deoxyadenosine monophosphate approved for use in young 
adults 18 years. Its long half life allows for once daily 
administration. It is available only in tablet form, and may 
be taken with or without food, although its absorption is 
enhanced with food. Tenofovir is excreted unchanged by the 
kidneys; renal tubular toxicity is a rare side effect of therapy. 
However, monitoring of renal function is recommended 
during tenofovir therapy, and dose adjustment is necessary 
in renal failure. Other side effects include nausea, diarrhea, 
rash, and flatulence. Lack of pediatric dosing information 
and possible bone toxicity preclude the use of tenofovir in 
prepubertal children (Tanner Stages 1–3) or those 18 years.20 
However use of tenofovir may be considered in older post-
pubertal children.3 Drug interactions with numerous ARVs 
are seen, and dose adjustment may be necessary. Tenofovir 
increases serum concentrations of didanosine, requiring 
decreased didanosine dose, while dose increases are necessary 
for tipranavir, since tenofovir decreases serum concentrations 
of this medication. Concomitant lopinavir/ritonavir may 
increase serum tenofovir levels, possibly resulting in greater 
tenofovir toxicity.21 Tenofovir also decreases serum levels of 
atazanavir. If tenofovir and atazanavir are co-administered, 
ritonavir boosting should be used with the atazanavir; use of 
unboosted atazanavir with tenofovir is not recommended.
Non-nucleoside reverse transcriptase 
inhibitors (NNRTis)
The NNRTIs also inhibit the enzyme reverse transcriptase. 
By binding noncompetitively to the hydrophobic pocket close 
to the polymerase catalytic site of the reverse transcriptase, 
NNRTIs decrease reverse transcriptase polymerizing activity. 
NNRTIs include nevirapine, efavirenz, delavirdine, and 
etravirine, but only efavirenz and nevirapine have pediat-
ric indications. Although NNRTIs have low pill burdens 
and cause less hyperlipidemia and fat maldistribution, the 
rapid emergence of class resistance, and high frequency of 
cutaneous reactions associated with these medications are 
drawbacks to their use. Both efavirenz and nevirapine have 
very long half-lives and may remain detectable for up to 
21 days after discontinuation. Most NNRTIs are metabolized 
by the liver and drug interactions are possible with this class 
of medications.3
efavirenz (Sustiva®)
Efavirenz is the preferred NNRTI in children due to its 
low toxicity and once daily administration. However, it 
is formulated only as a capsule and approved only for 
children 3 years weighing 10 kg. Its absorption is 
enhanced on an empty stomach. Dosing for efavirenz is 
usually weight-based, but body surface area dosing has also 
been utilized, especially in regimens containing lopinavir/
ritonavir.22,23 Efavirenz is well-tolerated, but neuropsychiatric 
side effects such as dizziness, fatigue, insomnia, agitation, 
impaired concentration, vivid dreams, and suicidal ideation 
may occur with its use. For this reason, it should be admin-
istered at bedtime, and cautious use is suggested in patients 
with psychiatric disease. Rash occurs less commonly than 
with nevirapine, but lipid abnormalities have been reported. 
Efavirenz is teratogenic and its use should be avoided in 
women of reproductive age unless adequate contraception 
is ensured. Efavirenz is a mixed inducer/inhibitor of cyto-
chrome P450 3A4 enzymes and is associated with many drug 
interactions. It may reduce levels of lopinavir, saquinavir, 
and indinavir, if co-administered with these drugs. Concomi-
tant administration of midazolam and triazolam should be 
avoided. Studies have demonstrated the virologic efficacy 
of efavirenz in combination with NRTIs and/or PIs in the 
treatment of pediatric HIV infection.16,24–26
Nevirapine (viramune®)
Nevirapine was the first NNRTI approved by the US Food and 
Drug Administration (FDA). It is available both as a tablet 
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without food. Nevirapine should be used in children 3 years, 
or in children requiring a liquid NNRTI formulation, if an 
NNRTI-based regimen is desired. It has been proven safe and 
efficacious in pediatric clinical trials.27,28 The most common 
side effect is rash, seen in 5% of treated children, usually 
during the second week of therapy.10 Erythema multiforme, 
Stevens–Johnson syndrome, and toxic epidermal necrolysis 
have been reported; nevirapine should be discontinued in the 
case of a severe rash; milder skin eruptions generally resolve 
within 1–2 weeks and do not require drug discontinuation. 
Initiation of half-dose nevirapine therapy, followed by 
stepwise dose escalation over a two-week period allows for 
autoinduction of cytochrome p450 metabolizing enzymes 
CYP3A and 2B6, resulting in increased drug clearance and 
decreased cutaneous toxicity. Although, life-threatening 
hepatotoxicity has also been reported in adults with higher 
CD4 counts, usually during the first 12 weeks of therapy, 
nevirapine-induced hepatotoxicity is seen infrequently in 
children.29 Concomitant use of other potentially hepatotoxic 
medications should be avoided. Serum transaminase levels 
should be checked every two weeks during the first month 
of nevirapine therapy, then monthly for three months, and 
then every three to four months. Because of potential hepa-
totoxicity, nevirapine should not be used in post-pubertal 
females with CD4  250 or males with CD4  400, unless 
benefits of therapy outweigh the risks.30,31 Nevirapine also 
has the potential for numerous drug interactions as it acts as 
an inducer of hepatic cytochrome p450 enzymes including 
CYP3A and 2B6. Certain PI doses may require adjustment 
if given with nevirapine.
Two other NNRTIs have been approved for HIV-infected 
adults but not children. These include Delavirdine (Rescriptor) 
and Etravirine (Intelence). Delavirdine is no longer manu-
factured Etravirine is a second generation NNRTI active 
against viruses with resistance to first generation NNRTIs 
that is useful in treatment-experienced adults. However, this 
medication has not been adequately studied in children and 
cannot be recommended at the present time.3
Protease inhibitors
There are seven protease inhibitors (PIs) currently approved 
for use in children. The use of combination therapy with PIs 
in HIV-infected children and adolescents has been shown 
to reduce mortality by 67%.32 PIs inhibit the viral enzyme 
protease by binding competitively to the enzyme, limiting 
the production of mature infectious virions. PIs have a high 
genetic barrier for the development of drug resistance and are 
potent inhibitors of viral replication. However, their use is 
complicated by high pill burdens, numerous drug interactions, 
and frequent metabolic side effects. Abnormalities of 
glucose metabolism (hyperglycemia, insulin resistance, 
or diabetes mellitus) and changes in body fat distribution 
(lipodystrophy) and dyslipidemias (hypertriglyceridemia, 
hypercholesterolemia) are commonly attributed to this class of 
medications. In addition, PIs have been associated with serum 
transaminase elevation, hepatitis, pancreatitis, and spontane-
ous bleeding in hemophiliacs. Unpalatable drug formula-
tions and large pill size are drawbacks to PI use. Also, drug 
interactions occur frequently with this class of medications 
that are metabolized by the hepatic cytochrome P450 enzyme 
system, necessitating possible dose adjustments. For example, 
decreased levels of rifabutin, rifampin, and ketoconazole may 
be seen if these medications are co-administered with PIs and 
interactions may be seen with certain oral contraceptives.
Many PIs are combined with low dose ritonavir in adults 
(boosted PI or pharmacoenhancer). Ritonavir inhibition of 
the cytochrome p450 3A4 enzyme results in diminished 
metabolism of the second PI. However, many boosted 
PI combinations have not been studied in HIV-infected 
children, and there is potential for enhanced drug interac-
tions and hyperlipidemia. Current guidelines recommend 
the use of three boosted PI regimens (lopinavir, atazanavir 
and fosamprenavir) in HIV-infected children.3
Lopinavir/ritonavir (Kaletra®)
This co-formulated product is the preferred PI in children. It is 
available both as a liquid and a tablet, and may be administered 
to infants as young as two weeks.3 Although co-administration 
with food is required for the liquid formulation, the tablet may 
be administered with or without food. The liquid formulation 
has a bitter taste, resulting in a poor patient acceptance rate. 
Common side effects include gastrointestinal symptoms such 
as nausea, vomiting, and diarrhea, rash, asthenia, lipid abnor-
malities, and headache. Changes in body fat composition occur 
less commonly than with other PIs, but lopinavir/ritonavir does 
interact with multiple medications including atorvastatin, ethi-
nylestradiol, rifabutin, ketoconazole, itraconazole, and calcium-
channel blockers.33 Increased dosages of lopinavir/ritonavir are 
required if this medication is co-administered with nevirapine 
or efavirenz. Lopinavir/ritonavir has proven virologic and 
immunologic efficacy in the treatment of both treatment-naïve 
and treatment-experienced HIV-infected children.9,33–35
Nelfinavir (Viracept®)
Nelfinavir was the first PI recommended for pediatric use 
and has been extensively studied in children.9,36 At the Therapeutics and Clinical Risk Management 2009:5 475
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present time, nelfinavir is recommended as an alternative 
PI for children aged 2 years.3 The liquid formulation 
is compounded by mixing nelfinavir powder with water. 
Nelfinavir requires administration with food and is usu-
ally dosed twice daily, but younger children require thrice 
daily administration. Nelfinavir is well-tolerated; diarrhea 
is the most common side effect. Other frequent side effects 
include asthenia, abdominal pain, rash, and lipid abnormali-
ties. Less commonly, fat redistribution and exacerbation of 
chronic liver disease may occur.30 In 2007, nelfinavir was 
temporarily banned for use in children aged 2 years after 
it was found to contain ethyl methanesulfonate (EMS), a 
potential carcinogen.37 However, the product was reformu-
lated and now meets acceptable EMS limits as per the FDA 
recommendation for use in children and pregnant women.3,38 
A number of drug interactions are seen between nelfinavir 
and certain antibiotics, proton pump inhibitors, corticosteroid 
preparations, and benzodiazepines. In addition, nelfinavir 
may interact with other ARV medications including a number 
of protease inhibitors, didanosine, and nevirapine.
Atazanavir (Reyataz®)
Boosted atazanavir is currently recommended as an alterna-
tive PI in children 6 years. Use of unboosted atazanavir 
in children aged 13 yrs (and/or 39 kg) is generally not 
recommended due to lack of pediatric dosing informa-
tion, but may be considered for pediatric use under special 
circumstances (children aged 13 years weighing 39 kg).3,39 
Atazanavir is administered once daily with food. Its most 
common side effect is asymptomatic hyperbilirubinemia but 
jaundice, headache, fever, arthralgia, depression, insomnia, 
dizziness, nausea, vomiting, diarrhea, and paresthesias 
may occur. PR interval prolongation has been reported 
with first-degree and second degree atrioventricular 
block. Therefore atazanavir should be used cautiously in 
patients with arrhythmias, or those receiving other agents 
such as calcium channel blockers that may affect the PR 
interval. Skin rash is most often mild to moderate, but 
Stevens–Johnson syndrome has been reported. Compared 
with other PIs, atazanavir has less effect on serum lipids 
and causes less fat redistribution. Use of atazanavir is also 
complicated by numerous drug interactions, as it is both 
a substrate and inducer of the CYPA4 enzyme system. 
Only boosted atazavanir should be co-administered with 
tenofovir. As efavirenz and nevirapine may decrease 
plasma levels of atazanavir, nevirapine co-administration 
should be avoided; efavirenz and boosted atazanavir may 
be co-administered only in treatment-naïve patients but not 
in treatment-experienced patients. Caution is also needed 
with co-administration of H2-receptor antagonists and 
proton pump inhibitors. Atazanavir should be given one 
hour after buffered didanosine, if these 2 medications are 
given together.39
Fosamprenavir (Lexiva®)
Fosamprenavir is a prodrug of amprenavir that is formulated 
as both a liquid and a tablet that may be administered with 
or without food. Boosted fosamprenavir is currently recom-
mended as an alternative PI in children aged 6 years, and 
for use without ritonavir in children aged 2 years under 
special circumstances. It is administered once daily to adults 
but twice daily dosing is recommended for HIV-infected 
children.3 Selection of dosing regimen depends upon whether 
the patient is treatment-naïve or treatment-experienced. The 
main advantage of fosamprenavir use is a low pill burden; 
numerous drug interactions are the major drawback to its 
use. Side effects include rash, gastrointestinal symptoms, 
headache, perioral paresthesias, and lipid abnormalities. Less 
common side effects include severe rash, fat redistribution, 
neutropenia, and elevation of serum creatinine levels. Fosam-
prenavir is a sulfonamide that should be used cautiously in 
patients reporting sulfonamide allergy.39
Ritonavir (Norvir®)
Ritonavir has been available for long-term pediatric use. This 
potent PI is available as a liquid formulation that must be 
administered with food, but has a poor acceptance rate due to 
its bitter taste. Numerous drug interactions due to inhibition 
of the cytochrome P450 isoenzyme CYP3A complicate its 
use.30 Side effects include gastrointestinal symptoms, head-
aches, circumoral paresthesias, and lipid abnormalities. Less 
commonly, fat redistribution and exacerbation of chronic 
liver disease may occur. Caution is recommended when 
administering this drug to patients with moderate-severe 
hepatic impairment. PR interval prolongation and allergic 
reactions including urticaria, angioedema, and bronchospasm 
have also been reported.9
Saquinavir (invirase®)
Saquinavir is not approved for use in children but is recom-
mended for use in combination with low dose ritonavir under 
special circumstances.3 Currently, it is available only in a soft 
gel tablet form that is administered twice daily with food. Side 
effects include gastrointestinal intolerance, paresthesias, head-
ache, rash, and lipid abnormalities. Less commonly, fat redis-
tribution and exacerbation of chronic liver disease may occur. 
Due to low bioavailability, this PI should never be used as a Therapeutics and Clinical Risk Management 2009:5 476
Schuval Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
sole PI and requires boosting with another PI such as ritonavir.30 
Numerous drug interactions also complicate its use.
indinavir (Crixivan®)
Indinavir is a PI administered only via capsule that requires 
thrice daily dosing. It is not available in liquid formulation 
and the risk of renal toxicity (hematuria, nephrolithiasis) 
limits its use in children. However, it may be considered 
for use, along with ritonavir boosting, in adolescents who 
weigh enough to receive adult dosing. It should be taken on 
an empty stomach and patients receiving this PI should be 
advised to increase their fluid intake.30
Two other PIs commonly used for the treatment of HIV-
infected adults, but not recommended for use in children 
at this time include tipranavir and darunavir. Tipranavir 
(Aptivus®) has proven useful for PI-experienced adults with 
multiple PI mutations in the viral genome. Although it was 
approved for use in children aged 2 through 18 years in 
2008, lack of pediatric data limits its use in children. It is 
not recommended for initial therapy but may be useful in 
children with treatment failure.3 It is available as a tablet and 
an oral solution and may be given with or without food. Drug 
interactions occur frequently. Common side effects include 
gastrointestinal symptoms, fatigue, headache, rash, lipid 
abnormalities, and serum transminase elevation. Less com-
mon side effects include fat redistribution, hepatitis/hepatic 
decompensation, and epistaxis. Rarely, intracranial hemor-
rhage has been seen. Darunavir (Prezista®), a potent PI with 
activity against multidrug-resistant HIV, was approved for use 
in HIV-infected adults in 2006. Although it was approved for 
children aged 6 years in 2008, this medication is not recom-
mended for initial therapy in children secondary to high pill 
burden and limited pediatric data. However, its use may be 
considered in children with treatment failure.3 It is available 
only in a tablet that should be given with food, and boosted 
with ritonavir. Side effects include gastrointestinal symptoms 
(nausea, vomiting, diarrhea, abdominal pain), headache, and 
fatigue. Less commonly, rash, fever, lipid abnormalities, and 
serum transminase elevation have been reported. Numerous 
drug interactions have also been described. Both darunavir 
and tipranavir contain a sulfonamide component and should 
be used cautiously in patients reporting sulfonamide allergy. 
Amprenavir (Agenerase®) is a PI that is no longer manufac-
tured and has largely been replaced by fosamprenavir.
Fusion inhibitors
Fusion inhibitors inhibit the entry of HIV-1 into host cells by 
preventing fusion of the viral and cell membranes.
enfuvirtide (Fuzeon®)
Enfuvirtide is a synthetic 36-amino acid peptide that binds to the 
gp41 of the HIV viral envelope. It is administered twice daily via 
subcutaneous injection.40 Enfuvirtide is recommended for use in 
treatment-experienced HIV-positive adults with advanced HIV 
infection. Although it was approved for children aged 6 years, 
its use is recommended only in cases of treatment failure. Most 
patients experience injection site reactions, which are usually 
mild.41 Increased rates of bacterial pneumonia and local site 
cellulitis have been reported. Rare systemic hypersensitivity 
reactions have been reported in 1% of patients and require 
permanent discontinuation of this medication.
entry inhibitors
Entry inhibitors block the binding of HIV-1 to the human 
CCR5 chemokine receptor, preventing viral entry into the 
CD4 cell.
Maraviroc (Selzentry®)
Maraviroc is an R5-specific inhibitor approved in 2007 for use in 
HIV-infected patients aged 16 years with R5- tropic virus and 
multidrug-resistant virus. A co-receptor tropism assay should 
be performed prior to the initiation of therapy with any CCR5 
inhibitor to confirm that a patient’s dominant virus population is 
R-5, rather than X4. Only patients with R5- tropic virus would 
be expected to respond to Maraviroc; it is ineffective against 
those with dual-tropic or predominantly X-4 virus. Maraviroc 
is not approved for use in children aged 16 years, but may 
be useful in cases of treatment failure. Common side effects 
include cough, fever, upper respiratory infection (URI), rash, 
musculoskeletal symptoms, abdominal pain, and dizziness. 
Less common side effects include cardiovascular abnormalities 
and hepatic failure. There are multiple drug interactions which 
may affect its dosing. It may be given with or without food, but 
decreased absorption occurs with fatty meal administration.6,42
integrase inhibitors
Integrase inhibitors inhibit proviral DNA-strand trans-
fer, interfering with insertion of viral DNA into the host 
genome.
Raltegravir (isentress®)
Raltegravir was approved in 2007 for use in treatment-
experienced HIV-infected patients aged 16 years with mul-
tidrug-resistant virus. It is dosed twice daily in adults but lack 
of pediatric data and unavailability of a pediatric formulation 
limit its use in children at this time.43,44 Side effects include 
diarrhea, nausea, URI symptoms, and dizziness.Therapeutics and Clinical Risk Management 2009:5 477
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Fixed drug combinations
A number of fixed drug combination (FDCs) have proven 
convenient for ART administration in adults. There are cur-
rently five FDCs available including Combivir®, Trizivir®, 
Epzicom®, Truvada®, and Atripla®. Combivir® consists 
of zidovudine/lamivudine; Trizivir® contains zidovudine, 
lamivudine, and abacavir. Lamivudine and abacavir are 
combined within Epzicom® while Truvada® contains com-
bined emtricitabine and tenofovir. Atripla® is a once daily 
pill containing emtricitabine, tenofovir, and efavirenz. The 
main advantage of FDCs is ease of use with lower pill 
burdens. However, providing the correct dose for children 
may be difficult with FDCs, and underdosage may occur 
in children who may require higher doses relative to body 
weight compared with adults.37
Future treatment/novel therapies
Pediatric studies are currently under way to determine the 
safety and efficacy of ARV agents such as etravirine and teno-
fovir, which are currently approved for HIV-infected adults, 
but not for children.20 NRTIs in development for adult use 
include elvicitabine, racivir and apricitabine, while rilpivirine 
is a second generation NNRTI under study.45 Sifuvirtide is a 
next-generation fusion inhibitor in development.46 Experimen-
tal chemokine receptor inhibitors include the CCR5 antagonist 
Vicriviroc and CXCR4 antagonists.47,48 Elvitegravir is a once 
daily integrase inhibitor being studied in adults. Ibalizumab 
is an anti-CD4 monoclonal antibody that interferes with HIV 
viral entry. New classes of ART under investigation include 
inhibitors of viral transcription, translation, and maturation.
Recommendations from current 
pediatric guidelines
The first guidelines for treatment of pediatric HIV infection 
were issued by the US Working Group on Antiretroviral 
Therapy and the Medical Management of HIV-Infected 
Children in 1993 and have since undergone numerous 
revisions. These guidelines include recommendations for 
the selection of initial and subsequent regimens, and contain 
both preferred and alternate regimens for the treatment of 
HIV-infected children, as well as detailed prescribing infor-
mation for all pediatric and adolescent ARV medications.3
Initiation of antiretroviral therapy 
in antiretroviral-naïve children
The decision to initiate ART is based upon disease severity, 
risk of disease progession, and availability of appropriate 
and palatable drug formulations (Table 2). Benefits of early 
therapy include preservation of immune function, prevention 
of disease progression, and possible lowering of the viral 
set point. Delaying the initiation of therapy may promote 
improved future medication adherence, reduce drug toxicity, 
and minimize drug resistance. Although the optimal timing 
of initial therapy is controversial in HIV-infected adults, most 
HIV specialists agree that ART is indicated for all HIV-infected 
infants aged 1 year as they are at high risk of disease progres-
sion. Early ART has been shown to decrease the risk of AIDS 
and death in perinatally-infected infants.49 Treatment is also 
recommended for any child aged 1 year with moderate (most 
clinical category B conditions) or severe symptoms, including 
AIDS (Category C), regardless of CD4 count or HIV RNA 
level as HIV disease progression is likely to occur in these 
children (Table 3).50 Current guidelines also advocate treat-
ment of any child aged 1 year with CD4 lymphocytopenia 
for age, and for older children (5 years) who are symptomatic 
or have CD4 lymphocytopenia for age (Table 2). Thus, ART 
would be indicated for children aged 1 to 5 with CD4 25%, 
or children aged 5 years with CD4 350 cells/mm3.
ART may be considered for children aged 1 year 
with normal CD4 for age and high viral load (plasma 
RNA 100,000 copies/mL), even in the absence of 
symptoms or presence of mild symptoms (clinical catego-
ries N, A, or the selected clinical category B conditions of 
bacterial infection or lymphoid interstitial pneumonitis (LIP). 
Treatment may be deferred in children aged 1 year who 
lack symptoms or have mild symptoms, and have normal 
CD4 for age and HIV RNA 100,000 copies/mL, as they are 
at low risk for HIV disease progression. Untreated children 
should be monitored closely over time with periodic CD4 
counts, HIV RNA levels, and clinical follow-up to determine 
whether treatment should be initiated.
Treatment readiness and the ability of the child and 
the caregiver to adhere to a prescribed regimen should 
be assessed prior to the initiation of therapy. Comorbid 
conditions such as tuberculosis, hepatitis B or C infection, 
or renal or liver disease may influence choice of ARV 
medication. Laboratory assessment prior to initiation of 
therapy should include CD4 count/percentage, HIV RNA 
level, viral resistance testing (genotype or phenotype), 
complete blood count with differential, serum chemistries 
including hepatic enzymes, serum lipase and amylase, and 
serum lipids (triglycerides and cholesterol). CD4 percent-
age is preferred for immunologic monitoring of children 
aged 5 years, whereas absolute CD4 count is a better 
immunologic parameter in older children.51 Five viral load Therapeutics and Clinical Risk Management 2009:5 478
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assays have been approved by the FDA for quantitation of 
HIV RNA copy number. None is preferred but continued 
use of the same assay over time is recommended for indi-
vidual patients.
Types of regimens
Most regimens include triple drug combinations consisting 
of two NRTIs with either an NNRTI (NNRTI-based regi-
men) or a boosted PI (PI-based regimen) (Table 4). Under 
special circumstances, a triple NRTI regimen consisting 
of zidovudine, lamivudine, and abacavir may be used.3 
Advantages of NNRTI-based regimens include ease of 
administration with low pill burden and decreased incidence 
of lipid abnormalities and fat maldistribution, compared 
with PI-based regimens.37 However, cutaneous side effects 
as well as potential drug interactions, and development of 
cross-resistance among NNRTIs are drawbacks to these 
regimens.
PI-based regimens are potent but their use is compli-
cated by high pill burdens, frequent drug interactions, and 
drug toxicity.37 The main advantage of these regimens is a 
high genetic barrier to the development of drug resistance.9 
Triple NRTI regimens are generally well-tolerated by chil-
dren as they have few side effects, pediatric formulation 
availability, and ease of use.18 This type of regimen will 
preserve NNRTIs and PIs for future use. Also, because of 
the a risk of a life-threatening hypersensitivity reaction to 
abacavir, use of the triple NRTI regimen containing zid-
ovudine, lamivudine, and abacavir is recommended only 
under special circumstances when a preferred or alternate 
NNRTI-based or PI-based regimen cannot be used.3 Other 
NRTI combinations such as tenofovir/abacavir/lamivudine 
or tenofovir/didanosine/lamivudine are not recommended 
as initial therapy for HIV-infected children due to inferior 
virologic potency.52
The “Guidelines for the Use of Antiretroviral Agents 
in Pediatric HIV Infection”contain both preferred and 
alternate dual NRTI combinations to be used with either 
an NNRTI or PI-based regimens (Table 4). These various 
NRTI combinations have been studied and proven safe, 
effective, and durable in children.13,16,36,53,54 The combina-
tion of zidovudine and lamivudine is the most studied in 
children and is well-tolerated.11 Although less data is avail-
able on its pediatric use, the similarity of emtricitabine led 
to its selection as a possible substitute for lamivudine for 
dual NRTI use.16 The therapeutic efficacy of zidovudine 
in HIV-infected children was first reported by the AIDS 
Clinical Trials Group (ACTG) 152 study team, which 
compared zidovudine monotherapy, didanosine mono-
therapy, and combined zidovudine/didanosine in 831 HIV+ 
symptomatic children. Combined zidovudine/didanosine 
therapy and didanosine monotherapy were proven supe-
rior to zidovudine.55 A 2001 study compared the safety, 
tolerability, and efficacy of dual zidovudine/lamivudine 
versus triple therapy with zidovudine/lamivudine/abaca-
vir in a cohort of 205 children and reported superiority of 
the three-drug combination compared with the two-drug 
regimen.18
The “Guidelines for the Use of Antiretroviral Agents in 
Pediatric HIV Infection” also lists ARV medications that 
are not recommended for use in HIV-infected children at 
any time. Single agent monotherapy or dual NRTI therapy 
Table 2 indications for treatment of Hiv-infected children.   Adapted from the Guidelines for the Use of   Antiretroviral   Agents in Pediatric 
Hiv infection3
INITIATE TREATMENT
All infants 1 year
Any infant or child with AIDS or significant HIV symptoms (Clinical Category B*,C)
Child ages 1–5 years with CD4  25% (regardless of symptoms or Hiv RNA level)
Child 5 years with CD4  350 cells/mm3
CONSIDER TREATMENT
Child 1–5 years with CD4  25% and Hiv RNA  100,000 copies/mL (regardless of symptoms)
Child 5 years with CD4  350 cells/mm3 and Hiv RNA  100, 000 copies/mL
DEFER TREATMENT
Child age 1–5 years with no symptoms/mild symptoms** + CD4 25% + Hiv RNA  100,000 copies/mL
Child age 5 years with no symptoms/mild symptoms** + CD4  350 cells/mm3 and Hiv RNA  100,000 copies/mL
Notes: *except single episode of bacterial infection or LIP. **with a single episode of bacterial infection or LIP.Therapeutics and Clinical Risk Management 2009:5 479
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Table 3 1994 Revised human immunodeficiency virus pediatric classification system; clinical categories (updated February 28, 2008)50
Category N: Not symptomatic: Children who have no signs of symptoms considered to be the result of Hiv infection or who have only one of the 
conditions listed in Category A.
Category A: Mildly symptomatic: Children with two or more of the following conditions listed in categories B and C:
Lymphadenopathy ( 0.5 cm at more than two sites: bilateral at one site)
Hepatomegaly
Splenomegaly
Dermatitis
Parotitis
Recurrent or persistent upper respiratory infection, sinusitis, or otitis media
Category B: Moderately symptomatic: Children who have symptomatic conditions, other than those listed for category A or category C, that are 
attributed to Hiv infection. examples of conditions in clinical category B include, but are not limited to, the following:
Anemia (8gm/dL), neutropenia (1000 cells/mm3), or thrombocytopenia (100,000 cells/mm3) persisting  30 days
Bacterial meningitis, pneumonia, or sepsis (single episode)
Candidiasis, oropharyngeal (ie,thrush) persisting for 2 months in children aged 6 months
Cardiomyopathy
Cytomegalovirus infection with onset before age 1 month
Diarrhea, recurrent or chronic
Hepatitis
Herpes simplex virus (HSv) stomatitis, recurrent (ie, more than two episodes within 1 year)
HSv bronchitis, pneumonitis, or esophagitis with onset before age 1 month
Herpes zoster (ie, shingles) involving at least two distinct episodes or more than 1 dermatome
Leiomyosarcoma
Lymphoid interstitial pneumonitis (LiP) or pulmonary lymphoid hyperplasia complex
Nephropathy
Nocardiosis
Fever lasting 1 month
Toxoplasmosis with onset before age 1 month
varicella, disseminated (ie, complicated chickenpox)
Category C: Severely symptomatic: Children who have any condition listed in the 1987 surveillance case definition for acquired immunodeficiency 
syndrome (below) with the exception of LiP (which is a category B condition)
Serious bacterial infections, multiple or recurrent (ie, any combination of at least two culture-confirmed infections within a 2 year period) of the following 
types: septicemia, pneumonia, meningitis, bone or joint infection, or abcess of an internal organ or body cavity (excluding otitis media, superficial skin or 
mucosal abcesses, and indwelling catheter-related infections)
Candidiasis, esophageal or pulmonary (bronchi, trachea, lungs)
Coccidioidomycosis, disseminated (at site other than or in addition to lungs or cervical or hilar lymph nodes)
Cryptococcosis, extrapulmonary
Cryptosporidiosis or isosporiasis with diarrhea persisting 1 month
Cytomegalovirus disease with onset of symptoms at age 1 month (at a site other than liver, spleen, or lymph nodes)
Encephalopathy (at least 1 of the following progressive findings present for at least two months in the absence of a concurrent illness other than HIV 
infection that could explain the findings): a) failure to attain or loss of developmental milestones or loss of intellectual ability, verified by standard devel-
opmental scale or neuropsychological tests; b) impaired brain growth or acquired microcephaly demonstrated by head circumference measurements 
or brain atrophy demonstrated by computerized tomography or magnetic resonance imaging (serial imaging required for children 2 years of age); c) 
acquired symmetric motor deficit manifested by 2 or more of the following: paresis, pathologic reflexes, ataxia, or gait disturbance
Herpes simplex virus infection causing a mucocutaneous ulcer that persists for 1 month; or bronchitis, pneumonitis, or esophagitis for any duration 
affecting a child 1 month of age
Histoplasmosis, disseminated (at a site other than or in addition to lungs or cervical or hilar lymph nodes)
Kaposi’s sarcoma
Lymphoma, primary in brain
Lymphoma, small, noncleaved (Burkitt’s), or immunoblastic or large cell lymphoma of B-cell or unknown immunologic phenotype
(Continued)Therapeutics and Clinical Risk Management 2009:5 480
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should not be given, except for the use of zidovudine 
monotherapy in prenatal HIV exposure prophylaxis. 
Certain NRTI combinations (zidovudine/stavudine, 
lamivudine/emtricitabine, didanosine/stavudine) are not 
recommended for use as part of a HAART regimen. Other 
ARV medications not recommended for pediatric use include 
tenofovir, efavirenz (in the first trimester of pregnancy or 
in sexually active females of childbearing potential), and 
nevirapine (in adolescent females with CD4  250 cells/mm3 
or adolescent males with CD4  400, unless the benefits 
of therapy outweigh the risks). Pediatric use of unboosted 
saquinavir or combined indinavir/atazanavir is also not 
recommended.3
In addition, the “Guidelines for the Use of Antiret-
roviral Agents in Pediatric HIV Infection” include ARV 
medications/ART regimens that lack sufficient pediatric 
data at this time for use as initial therapy in treatment-naïve 
children. However, use of these agents may be considered 
for secondary therapy in certain treatment-experienced or 
older children/adolescents.3 Use of dual PI regimens or use 
of boosted PI regimens other than the three recommended 
alternate regimens (lopinavir/ritonavir, atazanavir/ritonavir, 
and fosamprenavir/ritonavir) are not recommended nor is 
use of unboosted atazanavir in children aged 13 years 
or 39 kg. Three-class regimens (NRTI + NNRTI + PI) 
should not be used. Contraindicated NRTI combinations 
include zidovudine/stavudine, lamivudine/emtricitabine, 
and stavudine/didanosine. Use of agents in newer classes 
including tipranavir, darunavir, maraviroc, raltegravir, 
etravirine, and enfuvirtide is also not recommended for 
initial therapy in HIV-infected children or adolescents at the 
present time but may be useful in cases of treatment failure. 
Indinavir has studied mostly in small uncontrolled trials in 
HIV-infected children, and is not currently FDA-approved 
in the pediatric age group, nor is it recommended for use as 
initial therapy.
Monitoring of children receiving 
antiretroviral therapy
HIV-infected children and adolescents should be closely 
monitored following the initiation of ART to determine 
whether the prescribed regimen is tolerable, and whether 
side effects are occurring. This is especially important 
during the first few weeks of therapy when adherence 
may be compromised. Therefore, clinical or telephone 
follow-up one to two weeks after starting new medica-
tion or undergoing a regimen change is recommended. 
Treated children should return to the clinic one month 
after beginning a new regimen for clinical and labora-
tory assessment consisting of complete blood count and 
differential, serum chemistries, serum lipids, CD4 count/
percentage, and HIV RNA level. Increases in CD4 cell 
count/percentage and decreases in HIV RNA levels signify 
a response to ART. Ideally, ART should reduce HIV RNA 
levels to undetectable levels (HIV RNA 50 copies/mL). 
ART-treated patients should then be seen at regular inter-
vals (every 3–4 months) to ascertain proper medication 
adherence, monitor for drug side effects, and to ensure 
efficacy of the medical regimen. CD4 count/percentage and 
plasma HIV RNA should be checked every 3–4 months. 
Serum amylase and lipase should be monitored in patient 
receiving didanosine and stavudine. A lipid panel should 
be obtained every 6–12 months.3
Immune reconstitution inflammatory syndrome (IRIS) 
may be seen in children during the first three months of 
initiating a new ART regimen. This occurs clinically as a 
worsening of symptoms of inflammation or infection due 
to increases in CD4 count. At this time, treatment of IRIS 
Table 3 (Continued)
Mycobacterium tuberculosis, disseminated or extrapulmonary
Mycobacterium, other species or unidentified species, disseminated (at site other than or in addition to lungs, skin, or cervical or hilar lymph nodes)
Mycobacterium avium complex or Mycobacterium kansasii, disseminated (at site other than or in addition to lungs, skin, or cervical or hilar lymph 
nodes)
Pneumocystis jiroveci pneumonia
Progressive multifocal leukencephalopathy
Salmonella (nontyphoid) septicemia, recurrent
Toxoplasmosis of the brain with onset at 1 month of age
Wasting syndrome in the absence of a concurrent illness other than HIV infection that could explain the following findings: a) persistent weight loss 10% 
of baseline; OR b) downward crossing of atleast two of the following percentile lines on the weight-for-age chart (eg, 95th, 75th, 50th, 25th, 5th) in a child 1 
year of age; OR c) 5th percentile on weight-for-height chart on two consecutive measurements,  30 days apart PLUS 1) chronic diarrhea (ie, 2 loose 
stools per day for 30 days), OR 2) documented fever for 30 days, intermittent or constant)Therapeutics and Clinical Risk Management 2009:5 481
Pharmacotherapy of pediatric Hiv Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
is largely empiric, although antibiotics, antivirals, and 
corticosteroids have been used.56
Management of the treatment-
experienced child/treatment failure
A prompt change in the ART regimen should be considered 
for HIV-infected patients who are experiencing clinical HIV 
disease progression, immunologic deterioration, drug resis-
tance, or increasing HIV viral replication. Clinical features 
that may warrant a change in regimen include progressive 
neurodevelopmental deterioration, growth failure, or recurrent 
or severe infections. Any decreases in CD4 count or increases 
in HIV RNA levels should be confirmed by repeat laboratory 
testing prior to a medication switch. CD4 levels are based on 
age and absolute counts and percentages, and will normally 
decrease over time in children. Successful ART therapy 
should result in a 1.0 log10 decline in HIV RNA level from 
baseline after two to three months of therapy, but a slower 
decline may be seen in patients with higher initial HIV RNA 
levels. HIV RNA levels  400 copies/mL after six months of 
treatment or detectable HIV RNA after one year of treatment 
may represent virologic failure. It has been estimated that 
30%–80% of HIV-infected children will experience treatment 
failure within one year of treatment initiation.14 Children 
with treatment failure should be evaluated for medication 
adherence, drug intolerance, and possible drug interactions 
which may lessen the efficacy of the therapeutic regimen. 
Frequent medication regimen changes are not advisable for 
HIV-infected children since this may limit future treatment 
options. Thus, in certain circumstances, children may benefit 
from continuation of an ART regimen with more frequent 
monitoring of CD4 counts and HIV RNA levels.
Careful review of ART medication history and past drug 
resistance testing is recommended prior to initiating any 
medication change, as is a complete history and physical 
examination. When selecting a new regimen, it is important 
Table 4 initial therapy for Hiv-infected children.   Adapted from the Guidelines for the Use of Antiretroviral Agents in Pediatric Hiv 
infection3
A. NNRTI-BASED REGIMEN:
Preferred regimen Alternative regimen
efavirenz + 2 NRTis (3 years) Nevirapine + 2 NRTis (3years)
Nevirapine + 2 NRTis (3 years) (child unable to swallow capsule)
B. PI-BASED REGIMEN
Preferred regimen Alternative regimen Special circumstances
Lopinavir/ritonavir + 2 NRTis Atazanavir/ritonavir + 2 NRTis Fosamprenavir (unboosted) + 2 NRTis
(children 6 years) (children 2 years)
Fosamprenavir/ritonavir + 2 NRTiS Atazanavir (unboosted) + 2 NRTis
(children 6 years) (for treatment-naïve  
adolescents 3 years and 39kg)
Nelfinavir + 2 NRTis
(children 2 years)
C. TRIPLE NRTI REGIMEN Zidovudine + Lamivudine + Abacavir
Dual NRTI backbones for use in above regimens (A and B)
Preferred regimen Alternative regimen Special circumstances
Lamivudine + Abacavir* Zidovudine + Abacavir* Stavudine + Lamivudine
emtricitabine + Abacavir* Zidovudine + Didanosine Stavudine + emtricitabine
Didanosine + emtricitabine
Zidovudine + Lamivudine
Zidovudine + emtricitabine
Tenofovir** + Lamivudine
Tenofovir** + emtricitabine
Notes: *HLA B*5701 genetic testing recommended prior to therapy with use of abacavir contraindicated in patients found to be HLA B*5701-positive. 
**For Tanner Stage 4 or post-pubertal adolescents only who are unable to tolerate ritonavir + 2 NRTis (boost with ritonavir if tenofovir used). Saquinavir/
ritonavir + 2 NRTis for post-pubertal adolescents who weigh enough to receive adult doses).Therapeutics and Clinical Risk Management 2009:5 482
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to discontinue all medications to which the patient’s virus 
is resistant, and to avoid the initiation of any agents with 
possible cross resistance, to ensure that all agents are fully 
active. Cross resistance occurs commonly among NRTIs 
and NNRTIs. Another consideration in changing regimens 
is the preservation of future treatment options including use 
of novel agents. Caregivers should always discuss adherence 
issues and select a medication regimen that is acceptable to 
the patient in terms of drug formulation, pill burden, dosing 
frequency, and meal requirements, prior to prescribing a new 
antiretroviral regimen.
For children failing their first PI-based regimen, a change 
to an NNRTI-based regimen is recommended. Conversely, 
children failing a NRTI-based regimen should switch to a 
PI-based regimen. At least two and preferably three active 
agents should be used. In certain situations, use of a triple class 
regimen may be necessary if a potent dual NRTI backbone can-
not be identified. Consultation with a pediatric HIV specialist 
is recommended in patients with multidrug-resistant virus 
or those with limited treatment options. In the case of treat-
ment-experienced children aged 16 years failing their ART 
regimen, use of certain newer medications such as darunavir, 
maraviroc, or raltegravir may be considered. Enfuvirtide 
may also be useful for use in heavily treatment- experienced 
children and adolescents.3
Drug resistance
Viral resistance testing is recommended prior to initiation of 
ART or modification of a failing treatment regimen. Failure 
to maximally suppress viral replication may result in viral 
mutations that lead to drug resistance. However, a lack of drug 
resistance does not ensure that a medication will successfully 
reduce viral replication. Resistance assays may be genotypic 
(GT) or phenotypic (PT). GT assays detect specific viral muta-
tions in patients with HIV RNA levels  1,000 copies/mL. PT 
assays directly assess whether a viral isolate can grow in the 
presence of an ARV medication, measuring the 50% or 90% 
minimal inhibitory concentrations of a drug against the virus 
in vitro compared with a laboratory strain of wild-type virus. 
A third type of resistance assay (virtual phenotype) predicts 
the phenotype based on viral genotype. Although a number of 
resistance assays are commercially available, none is preferred 
for use in adults or children. However, continued use of the 
same type of resistance assay over time is recommended for 
individual patients. The assay should be performed before or 
within four weeks of drug discontinuation since reversion to 
wild-type virus may occur within four to six weeks of regimen 
discontinuation. Careful review of antiretroviral medication 
history and consultation with a pediatric HIV specialist may 
be needed for interpretation of viral resistance data. The 
International AIDS Society-USA (IAS-USA) maintains a list 
of mutations associated with clinical resistance to HIV which 
is updated regularly.57 Medication nonadherence should be 
suspected if persistent viremia is seen without evidence of 
viral resistance.
Medication adherence
Patients with poor medication adherence are at risk for the 
development of mutations and viral resistance. There are 
unique medication adherence issues that affect specific age 
groups. The caregiver/child relationship, HIV disclosure 
issues, and unpalatable drug formulations may adversely 
impact proper medication adherence in HIV-infected 
children, while denial of illness, lack of social support, and 
mental illness may impede proper ART administration in 
HIV-positive adolescents. For all treated patients, medication 
adherence must be evaluated at all medical visits. Any barri-
ers to adherence should be promptly identified and addressed. 
Some patients may benefit from the use of adherence aids 
such as medication timers, beepers, or diaries, while others 
may require the use of intensive pharmacologic or nursing 
services such as special medication packaging, or directly 
observed therapy. To ensure the success of an ART regi-
men, providers should simplify the medical regimen, using 
the lowest pill burden and formulations that are acceptable 
to the patient.58
Discontinuation/Interruption 
of therapy
There are certain situations where temporary discontinuation 
of ART may be indicated. These include significant drug 
toxicity, acute gastrointestinal illness, surgery, sedation, or 
patient/caregiver request. Severe medication toxicity neces-
sitates complete discontinuation of all ARV medications, but 
children with mild or moderate drug toxicity may not require 
an immediate change to the regimen, as some symptoms 
may resolve over time or be managed expectantly. ARV 
dose reduction is generally not recommended except in the 
case that therapeutic drug monitoring is available.3 Struc-
tured treatment interruptions (STIs) have been studied in 
HIV-infected adults to reduce drug toxicity, medication costs, 
and to provide virologic modification, that is, to return the 
patient’s virus to the wild-type virus state.31 However, overall 
immunological results with STIs have been disappointing, 
and since minimal data exist regarding STIs in children, STI 
cannot be recommended at this time.Therapeutics and Clinical Risk Management 2009:5 483
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Conclusion
Currently, HIV infection is often a chronic and manageable 
infection in adults and children. ARV medications from six 
classes are used sequentially in combination to suppress 
viral replication to maximal levels. Although the prog-
nosis of HIV infection has improved significantly since 
the 1980’s, viral resistance, drug toxicity, and medication 
nonadherence still present great challenges to successful 
treatment. Current practice guidelines for pediatric HIV 
infection provide updated recommendations to optimize 
the treatment of HIV infection.3 The current complex-
ity and rapidly evolving issues in HIV infection make it 
highly desirable for providers to consult with pediatric 
HIV specialists when caring for children infected with 
HIV. Additional pediatric studies are needed to develop 
new ARV medications, determine optimal ARV doses for 
HIV-infected children, enhance medication adherence, and 
to more effectively assess patients for drug toxicities and 
potential drug interactions.
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